Business
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 m
About this update from Bioage Labs, Inc.
[{"type":"image","alt":"BioAge Labs, Inc.","displaySize":"","headline":null,"caption":"BioAge Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Q4VL90BcRUw5eG_L017gw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0","width":300,"height":300}},"lazy":false},{"type":"text","content":"EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. All of the shares of common stock are being offered by BioAge.","length":969,"tagName":"p","attribs":{}},{"type":"text","content":"Goldman Sachs & Co. LLC, Piper Sandler and Citigroup are acting as joint book-running managers for the offering.","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"BioAge intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and manufacturing of its product candidates, including BGE-102 and further development of its NLRP3 and APJ programs, working capital, capital expenditures, reduction of indebtedness and for other general corporate purposes.","length":419,"tagName":"p","attribs":{}},{"type":"text","content":"The shares are being offered by BioAge pursuant to a registration statement on Form S-3 (No. 333-290688) that became effective on Nov...